scholarly journals Long term continuous Trastuzumab use for HER2-positive advanced breast cancer

2020 ◽  
Vol 6 (5) ◽  
Author(s):  
Haider Y. Shukur
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Loading Dose ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Trastuzumab Therapy ◽  
Locally Recurrent ◽  
Positive Breast Cancer

Objectives: Trastuzumab is the standard of care for locally advanced / metastatic her2-positive breast cancer. However, most of these patients will progress within 12 months of trastuzumab therapy. In contrast, there is a paucity of data available on the long-term treatment of patients with Trastuzumab. Our study was conducted to report efficacy and safety data for patients with locally recurrent / metastatic her2-positive breast cancer who received long-term therapy with Trastuzumab (≥5 years). Methods: This study was a prospective single-arm study of continuous Trastuzumab in patients who were histologically her2-positive and radiologically confirmed inoperable locally recurrent or metastatic breast cancer after complete one year of Trastuzumab plus chemotherapy (in hormone negative/hormone resistance) treatment then continuous Trastuzumab alone , or with hormone therapy (in sensitive hormone positive) without progression [complete or partial response or stable disease].  A total of 50 inoperable local recurrent and metastatic breast cancer  patients were treated with continuous intravenous Trastuzumab therapy administered according to the standard Trastuzumab every 3-weeks (8 mg/kg loading dose followed by 3-weekly 6  mg/kg maintenance doses starting 3 weeks after the loading dose) schedule, from January 2014 to January 2019 at the Najaf Cancer Clinic (NCC). Results: All 50 patients were evaluated with CR occur only in 20% (10/50) with an OAR of 50% (25/50). The cardiac status of these patients remained stable over time for the majority of patients with no marked changes in LVEF%. No treatment-related death was observed. The median OS and median PFS is 61 months and 20 months, respectively. Conclusion: In her2-positive recurrent and metastatic breast cancer patients, who initially respond to palliative treatment with trastuzumab, continuous trastuzumab can achieve a long-term tumor remission of several years and had significantly improved survival with tolerated and acceptable adverse events.

scholarly journals Long-term survival in a patient with metastatic HER2+ breast cancer undergoing lapatinib-based therapy for 6 years

ABOUTOPEN ◽  
2018 ◽  
Vol 4 (1) ◽  
pp. 8-10
Author(s):  
Salvatore Turano ◽  
Serafino Conforti
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Metastatic Breast ◽  
Considerable Improvement ◽  
Lung Involvement ◽  
Her2 Positive ◽  
Term Survival ◽  
Her2 Breast Cancer ◽  
Positive Breast Cancer

We report the case of a patient with HER2-positive breast cancer under adjuvant therapy (chemotherapy and trastuzumab) who developed a recurrence with bone (cervical spine) and lung involvement. After treatment with lapatinib and capecitabine, the patient remained stable with considerable improvement of her physical condition. After 6 years she is still in maintenance therapy with lapatinib. This case is among a number of long term surviving and long term responding patients, within an atypical subset of patients with HER2-positive metastatic breast cancer, in the presence of encephalic lesions (Oncology).

scholarly journals Cost of Illness of HER2-Positive and Recurrent HER2-Positive Breast Cancer – A Danish Register-Based Study from 2005 to 2016

2021 ◽  
Author(s):  
Maria Spanggaard ◽  
Jens Olsen ◽  
Kenneth Forsström Jensen ◽  
Michael Andersson
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Healthcare Costs ◽  
Early Stage ◽  
Labour Productivity ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Her2 Positive Breast Cancer ◽  
Positive Breast Cancer

Abstract Background: Information and knowledge about cost of illness and labour productivity in patients with HER2-positive early-stage and metastatic breast cancer treated with trastuzumab is limited. The aim of this study was to estimate the direct and indirect costs associated with treatment of HER2-positive breast cancer among patients with early-stage and metastatic breast cancer, treated with trastuzumab, in a 10-year period after diagnosis. Materials and Methods: This study included all Danish HER2-positive breast cancer patients (≥18 years) treated with trastuzumab between 2005 and 2016 identified in the Danish national registers. Among this population, patients experiencing metastatic breast cancer were identified. For the study populations, we estimated total healthcare costs and indirect costs for one year prior to the breast cancer diagnosis and up to 10 years after diagnosis compared with a group of matched controls free of breast cancer.Results: We identified 4,153 HER2-positive breast cancer patients, whereof 27% were identified with metastatic breast cancer. During the follow-up period of 10 years, we estimated excess healthcare costs of EUR 115,000 among the total study population compared to controls; EUR 211,000 among patients with recurrence; and EUR 89,000 among patients without recurrence. Healthcare costs were found to be highest in the first year after diagnosis and also peaked in the year after recurrence. Labour productivity was significantly lower among patients with recurrence 10 years after breast cancer diagnosis compared with controls.Conclusions: In this study, we estimated the direct and indirect cost associated with HER2-positive breast cancer to be significantly increased during the 10 years after diagnosis, specifically among patients experiencing recurrence of breast cancer.

Incidence of brain metastases after first line chemotherapy in breast cancer patients treated with or without trastuzumab

2006 ◽  
Vol 24 (18_suppl) ◽  
pp. 10582-10582
Author(s):  
G. Ferretti ◽  
A. Felici ◽  
M. Pino ◽  
P. Carlini ◽  
A. Fabi ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Brain Metastases ◽  
Metastatic Breast ◽  
Progression Free Survival ◽  
Breast Cancer Patients ◽  
First Line ◽  
Her2 Positive ◽  
Trastuzumab Therapy ◽  
Line Chemotherapy

10582 Background: Brain metastases during trastuzumab therapy have been frequently observed. Only a few studies have compared the risk of brain metastases in patients (pts) treated with or without trastuzumab. Methods: In our hospital, between Jun 2000 and September 2005, we conducted a retrospective study in 72 metastatic breast cancer pts treated with first-line mono-chemotherapy (CT) with paclitaxel or docetaxel or vinorelbine ± Trastuzumab (T). Results: Thirty-five pts with HER2 pos disease were treated with T associated with 1st line CT, while 37 pts (16 with HER2 positive tumor, 21 HER2 negative) were not treated with T (NT). Ten HER2 pos NT pts subsequently received T. The median follow-up was 21 months (range1–129); the median age was 54 (range 32–82); the median treatment duration was 5 months (range 1–29). The incidence of recurrence (R), progressive disease in brain (BR), progression free survival (PFS) after first line CT, and overall survival (OS) were reported below: (see Table) Conclusions: This study showed that, after first line chemotherapy, the use of T did not affect the incidence of BR in HER2 pos metastatic breast cancer pts. On the other hand, Her-2 neg seems to predict ‘per se‘ a lower incidence of cerebral spread of disease. [Table: see text] No significant financial relationships to disclose.

scholarly journals Clinical and molecular predictors of long-term response in HER2 positive metastatic breast cancer patients

2018 ◽  
Vol 19 (10) ◽  
pp. 879-886 ◽  
Author(s):  
Claudia Omarini ◽  
Stefania Bettelli ◽  
Cecilia Caprera ◽  
Samantha Manfredini ◽  
Federica Caggia ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Metastatic Breast Cancer ◽  
Cancer Patients ◽  
Metastatic Breast ◽  
Breast Cancer Patients ◽  
Her2 Positive ◽  
Term Response
Sign in / Sign up

Export Citation Format

Share Document